Evaluation of Tembusu virus single-round infectious particle as vaccine vector in chickens

IF 2.4 2区农林科学 Q3 MICROBIOLOGY Veterinary microbiology Pub Date : 2024-09-28 DOI:10.1016/j.vetmic.2024.110270

Yunzhen Huang , Zhe Liu , Junqin Zhang , Jiawen Dong , Linlin Li , Yong Xiang , Ruihuan Kuang , Shimin Gao , Minhua Sun , Yongjie Liu

{"title":"Evaluation of Tembusu virus single-round infectious particle as vaccine vector in chickens","authors":"Yunzhen Huang , Zhe Liu , Junqin Zhang , Jiawen Dong , Linlin Li , Yong Xiang , Ruihuan Kuang , Shimin Gao , Minhua Sun , Yongjie Liu","doi":"10.1016/j.vetmic.2024.110270","DOIUrl":null,"url":null,"abstract":"<div><div>Orthoflaviviruses are single-stranded RNA viruses characterized by highly efficient self-amplification of RNA in host cells, which makes them attractive vehicles for vaccines. Numerous preclinical and clinical studies have demonstrated the efficacy and safety of orthoflavivirus replicon vectors for vaccine development. In this study, we constructed Tembusu virus (TMUV) replicon-based single-round infectious particles (SRIPs) as vaccine development platform. To evaluate the potential of TMUV SRIPs as vaccines, we generated SRIPs that express the heterologous Fowl adenovirus 4 (FAdV-4) fiber2 protein and fiber2 head domain, named TMUVRP-fiber2 and TMUVRP-fiber2H, respectively. To assess the immunogenicity of the TMUV SRIPs, SPF chicks were intramuscularly inoculated twice. Our results showed that the TMUVRP-fiber2 vaccines elicited high levels of neutralizing antibodies. Challenge experiments showed that TMUVRP-fiber2 provided full protection against virulent FAdV-4 and significantly reduced viral shedding. Moreover, the immunogenicity of TMUVRP-fiber2H was significantly lower than that of TMUVRP-fiber2, which was reflected in the neutralizing antibody titer, survival rate, and virus shedding after challenge. Therefore, our results suggested that TMUV SRIPs are a promising novel platform for the development of vaccines for existing and emerging poultry diseases.</div></div>","PeriodicalId":23551,"journal":{"name":"Veterinary microbiology","volume":"298 ","pages":"Article 110270"},"PeriodicalIF":2.4000,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Veterinary microbiology","FirstCategoryId":"97","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S037811352400292X","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Orthoflaviviruses are single-stranded RNA viruses characterized by highly efficient self-amplification of RNA in host cells, which makes them attractive vehicles for vaccines. Numerous preclinical and clinical studies have demonstrated the efficacy and safety of orthoflavivirus replicon vectors for vaccine development. In this study, we constructed Tembusu virus (TMUV) replicon-based single-round infectious particles (SRIPs) as vaccine development platform. To evaluate the potential of TMUV SRIPs as vaccines, we generated SRIPs that express the heterologous Fowl adenovirus 4 (FAdV-4) fiber2 protein and fiber2 head domain, named TMUVRP-fiber2 and TMUVRP-fiber2H, respectively. To assess the immunogenicity of the TMUV SRIPs, SPF chicks were intramuscularly inoculated twice. Our results showed that the TMUVRP-fiber2 vaccines elicited high levels of neutralizing antibodies. Challenge experiments showed that TMUVRP-fiber2 provided full protection against virulent FAdV-4 and significantly reduced viral shedding. Moreover, the immunogenicity of TMUVRP-fiber2H was significantly lower than that of TMUVRP-fiber2, which was reflected in the neutralizing antibody titer, survival rate, and virus shedding after challenge. Therefore, our results suggested that TMUV SRIPs are a promising novel platform for the development of vaccines for existing and emerging poultry diseases.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

评估作为鸡疫苗载体的淡布苏病毒单轮感染颗粒。

正黄病毒是单链 RNA 病毒，其特点是 RNA 在宿主细胞中的高效自我扩增，这使它们成为极具吸引力的疫苗载体。大量临床前和临床研究都证明了正黄病毒复制载体用于疫苗开发的有效性和安全性。在本研究中，我们构建了基于坦布苏病毒（TMUV）复制子的单轮感染性颗粒（SRIPs）作为疫苗开发平台。为了评估TMUV SRIPs作为疫苗的潜力，我们生成了表达异源鸡腺病毒4（FAdV-4）纤维2蛋白和纤维2头部结构域的SRIPs，分别命名为TMUVRP-fiber2和TMUVRP-fiber2H。为了评估TMUV SRIPs的免疫原性，对SPF雏鸡进行了两次肌肉注射。结果表明，TMUVRP-纤维2疫苗可激发高水平的中和抗体。挑战实验表明，TMUVRP-纤维2对FAdV-4病毒提供了全面的保护，并显著减少了病毒的脱落。此外，TMUVRP-fiber2H 的免疫原性明显低于 TMUVRP-fiber2，这反映在挑战后的中和抗体滴度、存活率和病毒脱落上。因此，我们的研究结果表明，TMUV SRIPs 是一种很有前景的新型平台，可用于现有和新出现的家禽疾病疫苗的开发。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Veterinary microbiology 农林科学-兽医学

CiteScore

5.90

自引率

6.10%

发文量

221

审稿时长

52 days

期刊介绍： Veterinary Microbiology is concerned with microbial (bacterial, fungal, viral) diseases of domesticated vertebrate animals (livestock, companion animals, fur-bearing animals, game, poultry, fish) that supply food, other useful products or companionship. In addition, Microbial diseases of wild animals living in captivity, or as members of the feral fauna will also be considered if the infections are of interest because of their interrelation with humans (zoonoses) and/or domestic animals. Studies of antimicrobial resistance are also included, provided that the results represent a substantial advance in knowledge. Authors are strongly encouraged to read - prior to submission - the Editorials (''Scope or cope'' and ''Scope or cope II'') published previously in the journal. The Editors reserve the right to suggest submission to another journal for those papers which they feel would be more appropriate for consideration by that journal. Original research papers of high quality and novelty on aspects of control, host response, molecular biology, pathogenesis, prevention, and treatment of microbial diseases of animals are published. Papers dealing primarily with immunology, epidemiology, molecular biology and antiviral or microbial agents will only be considered if they demonstrate a clear impact on a disease. Papers focusing solely on diagnostic techniques (such as another PCR protocol or ELISA) will not be published - focus should be on a microorganism and not on a particular technique. Papers only reporting microbial sequences, transcriptomics data, or proteomics data will not be considered unless the results represent a substantial advance in knowledge. Drug trial papers will be considered if they have general application or significance. Papers on the identification of microorganisms will also be considered, but detailed taxonomic studies do not fall within the scope of the journal. Case reports will not be published, unless they have general application or contain novel aspects. Papers of geographically limited interest, which repeat what had been established elsewhere will not be considered. The readership of the journal is global.